Beth Faiman PhD, MSN, APN-BC,BMTCN, AOCN, FAAN, FAPO

home / authors / beth-faiman-phd-msn-apn-bc-bmtcn-aocn-faan-fapo

Articles

Bispecific Antibody Combinations In Relapsed Refractory Multiple Myeloma: TRIMM-2 Study

Ajai Chari, MD;Thomas G. Martin, MD;Jens Hillengass, MD, PhD ;Beth Faiman PhD, MSN, APN-BC,BMTCN, AOCN, FAAN, FAPO ;Louis Williams, MD;Shebli Atrash, MD ;Donna Catamero, ANP-BC, OCN, CCRC;Cesar Rodriguez Valdes, MD ;Shambavi Richard, MD

October 30th 2024

Panelists discuss how the TRIMM-2 study explores the potential of combining bispecific antibodies to enhance treatment efficacy in patients with relapsed/refractory multiple myeloma, potentially offering a novel therapeutic strategy for this difficult-to-treat condition.

Talquetamab, a GPRC5DxCD3 bispecific antibody (BsAb), for Relapsed Refractory Multiple Myeloma: MonumenTAL-1 Data and Implications

October 30th 2024

Panelists discuss how Talquetamab, a novel GPRC5DxCD3 bispecific antibody, shows promising results in treating relapsed/refractory multiple myeloma based on the MonumenTAL-1 trial data, potentially offering a new therapeutic option for this challenging patient population.